Shi Ying, Kong Wenming, Jiang Haiqin, Zhang Wenyue, Wang Chen, Wu Limei, Shen Yunliang, Yao Qiang, Wang Hongsheng
Department of Leprosy Control, Zhejiang Provincial Institute of Dermatology, Huzhou, People's Republic of China.
Hospital of Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, People's Republic of China.
Infect Drug Resist. 2022 Jul 27;15:4029-4036. doi: 10.2147/IDR.S368682. eCollection 2022.
Reports on antimicrobial resistance (AMR) of Mycobacterium () in Zhejiang Province are limited. Thus, this study aimed to investigate the drug resistance of new leprosy cases within several years and analyse the emergence of AMR mutations from Zhejiang Province.
This study enrolled 34 leprosy cases in Zhejiang Province, China, from 2018 to 2021. Gene mutation of WHO-recommended DRDRs (P1, B and A) and genes of compensatory AMR-associated DRDRs, including nth, A, C, B and 23S rRNA, were detected by amplification. Clinical data analysis was performed to investigate the epidemiological association of leprosy.
Of the 34 samples, 2 (5.9%) strains showed drug resistance, which were mutated to dapsone and ofloxacin, separately. Two single mutations in B were detected in different strains (5.9%), whereas one of the C mutation was also detected in one strain each (2.9%), which were proved to be polymorphs. No correlation of drug resistance proportion was identified in male vs female, nerve vs no nerve involvement, deformity vs no deformity and reaction vs non-reaction cases.
Results showed well control of leprosy patients in Zhejiang Province. Gene mutations of WHO-recommended DRDRs P1 and A confirmed the resistance to dapsone and ofloxacin. Compensatory AMR-associated mutations confirmed to be polymorphs still require further study to determine their phenotypic outcomes in . The results demonstrated that drug-resistant strains are not epidemic in this area. Given the few cases of leprosy, analysing the AMR of in Zhejiang Province more comprehensively is difficult. However, regular MDT treatment and population management in the early stage may contribute to the low prevalence of leprosy.
浙江省关于分枝杆菌()抗菌药物耐药性(AMR)的报告有限。因此,本研究旨在调查数年内新麻风病例的耐药情况,并分析浙江省AMR突变的出现情况。
本研究纳入了2018年至2021年中国浙江省的34例麻风病例。通过扩增检测世界卫生组织推荐的耐药决定区域(DRDRs,P1、B和A)的基因突变以及与AMR相关的补偿性DRDRs基因,包括nth、A、C、B和23S rRNA。进行临床数据分析以调查麻风的流行病学关联。
在34个样本中,2株(5.9%)显示耐药,分别对氨苯砜和氧氟沙星发生了突变。在不同菌株中检测到B区域的两个单突变(5.9%),而C区域的一个突变也在各一株中检测到(2.9%),这些被证明是多态性。在男性与女性、有神经受累与无神经受累、有畸形与无畸形以及有反应与无反应病例中,未发现耐药比例的相关性。
结果显示浙江省麻风患者得到了良好控制。世界卫生组织推荐的DRDRs P1和A的基因突变证实了对氨苯砜和氧氟沙星的耐药性。被证实为多态性的与AMR相关的补偿性突变仍需进一步研究以确定其在分枝杆菌中的表型结果。结果表明该地区耐药菌株未流行。鉴于麻风病例较少,全面分析浙江省分枝杆菌的AMR较为困难。然而,早期定期的多药联合治疗和人群管理可能有助于麻风的低流行率。